Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nexalin Technology, Inc. - Warrant (NQ: NXLIW )

0.5501 UNCHANGED
Streaming Delayed Price Updated: 9:54 AM EST, Nov 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.5501
Bid (Size) 0.4000 (10)
Ask (Size) 1.300 (11)
Prev. Close 0.5501
Today's Range 0.5501 - 0.5501
52wk Range 0.0075 - 0.7800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nexalin Technology CEO Provides Letter to Shareholders
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
From Nexalin Technology, Inc.
Via GlobeNewswire

Performance

YTD
+7234.67%
+7234.67%
1 Month
+292.93%
+292.93%
3 Month
+357.65%
+357.65%
6 Month
+232.39%
+232.39%
1 Year
+4900.91%
+4900.91%

More News

Read More
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
From Nexalin Technology, Inc.
Via GlobeNewswire
EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients
Via Benzinga
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
From Nexalin Technology, Inc.
Via GlobeNewswire
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
From Nexalin Technology, Inc.
Via GlobeNewswire
EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study
Via Benzinga
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Closing of $5.2 Million Public Offering
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
From Nexalin Technology, Inc.
Via GlobeNewswire
MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
Via ACCESSWIRE
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
From Nexalin Technology, Inc.
Via GlobeNewswire
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
From Nexalin Technology, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.